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Summary.-The serum concentrations of the radiosensitizer metronidazole have been determined in mice for both oral and intraperitoneal doses of the drug and these have been related to radiosensitization studies in murine tumour systems.
In preliminary work before a possible clinical trial the serum metronidazole concentration/time curves have been determined in 7 patients using single doses of metronidazole of up to 15 g. The data suggest that a linear relationship exists between the metronidazole dose expressed in mg/kg and the peak serum concentration.
The possibility of achieving radiosensitization of tumours in patients after tolerable doses of metronidazole is discussed in relation to enhancement ratios determined for in vitro and in vivto systems. It is concluded that predictions from in vitro systems give values that are probably too optimistic.
SEVERAL methods have been proposed
to reduce the problem caused by hypoxic, radioresistant tumour cells in the eradication of solid human tumours by radiotherapy (Duncan, 1973) . One method is to sensitize selectively the hypoxic cells using drugs (Emmerson and HowardFlanders, 1965 ). Many drugs have been identified which sensitize only hypoxic cells to the lethal effects of radiation and this property has been associated with high electron affinity in these compounds (Adams, 1973) . The discovery that metronidazole (Flagyl, May and Baker Ltd) selectively sensitized anoxic bacteria and bean roots (Foster and Willson, 1973) , mammalian cells in vitro (Asquith, Foster and WVillson, 1973; Chapman, Reuvers and Borsa, 1973; Asquith et al., 1974) and has a favourable pharmacology and toxicology in man, led to experiments to test the radiosensitizing efficiency of this drug in animal tumours and normal tissues in experimental animals.
No radiosensitization of normal skin in oxygen breathing mice was noted using metronidazole doses of up to 3 g/kg (Denekamp, Michael and Harris, 1974) . Metronidazole has been shown to reduce the dose needed to cure 50%o of C3H mice carrying first generation mammary tumour transplants from 4040 rad for oxygen breathing controls to 3100 rad for oxygen breathing metronidazole treated mice (ER § 1.3 ± 0.16). A dose of 3400 rad increases the cure rate from 20% in control mice to 700% in the drug treated mice (Begg, Sheldon and Foster, 1974) .
Metronidazole has also been shown to enhance radiation induced damage to a fast growing anaplastic sarcoma and first generation transplants of C3H mammary tumour when "time to regrow" and " cell loss " are used as tests of damage (Begg et al., 1974) . The dosage of metronidazole used to produce these tumour radiosensitizing effects in mice was high (1000-2500 mg/kg body weight).
However, experiments with the transplanted KHT sarcoma, using the lung colony assay technique to assess tumour cell survival, showed that a significant enhancement of radiation damage could be obtained using 250 mg/kg body weight (Rauth and Kaufman, 1974) . A significant reduction in the TCD50 of a C3H mouse mammary carcinoma using only 100 mg/kg has also been demonstrated (Stone and W; ithers, 1974 (McFadzean, 1969; Davies, 1967) . These preliminary estimates indicated that the dose to patients would be high (10 g) and outside the range of previous clinical experience. However, " overdoses " of up to 12 g, taken in a single dose with suicidal intent, of metronidazole were reported to have been well tolerated (Lewis and Kenna, 1965) . The serum concentrations of metronidazole after dosages of 4-15 g to 7 cancer patients receiving radiotherapy, together with the tolerance to repeated high doses, have been studied and are reported in this paper.
MATERIALS AND METHODS
(a) Murine serum concentration of metronidazole.-Four-month old WHT/Ht male mice in groups of 5 were given doses of metronidazole from 25 to 2500 mg/kg body weight either orally or intraperitoneally. The i.p. doses were given in saline and the oral doses were suspended in tragacanth mucilage. Blood was collected by heart puncture 15 and 30 min after drug administration. It was collected in non-heparinized tubes and allowed to clot, when the serum was separated by centrifugation and stored in separate tubes at 4°C until it could be measured.
(b) Human serum concentrations of metronidazole.-Seven patients in hospital for palliative radiotherapy to advanced malignancies were told about the object of this work and their permission obtained. Radiotherapy was commenced before any metronidazole was administered so that the degree of any nausea produced by the radiotherapy alone could be assessed. Thus, the assessment of any enhanced effect on the tumour tissue was precluded in this study.
As the upper small intestine is believed to be the site of maximal absorption of metronidazole, doses of 4-15 g were given 2 or 3 h after breakfast (it was felt unreasonable at the present stage to fast the patients to promote more rapid absorption). The drug was given as a single draught (crushed 400 mg tablets in 30 ml of liquid extract of liquorice B.P.C.) just after a venous blood specimen was taken for control purposes. Further venous blood specimens were taken at appropriate intervals and prepared for measurement as described above. Liver function tests (aspartate transaminase and alkaline phosphatase activities) and full blood counts were performed before treatment and regularly thereafter.
Metronidazole concentration determinations in the serum specimens were made using a polarographic technique (Kane, 1961) without further preparation, except for the removal of oxygen from the specimen by bubbling with pure nitrogen just before measurement.
Radiotherapy was continued, the radiation being given approximately 2 h after the drug was administered. metroni(lazole are linearly related to the dose administered (Fig. 1) . The full line is a linear relationship and is normalized to the 25-mg/kg point; the metronidazole concentration has been plotted on a logarithmic scale for convenience. Also shown in Fig. 1 (Asquith et al., 1974 (Regg et al., 1974; Rauth and Kaufman, 1974) The properties of metronidazole and its pharmacology (for references see Asquith et al., 1974) indicate that the drug equilibrates rapidly throughout the body and no evidence showing the drug to concentrate in any one tissue has been reported for either mice or man. Assuming this to be the case, then calculations suggest that even higher serum levels in man were expected (by about 20%) than were actually measured. This could be explained by assuming that the rate of absorption of metronidazole from the gastrointestinial tract is limited so that a significant amount is excreted before complete absorption can occur. As no toxic symptoms other than transient nausea have been experienced by any of the patients with serum levels of up to 340 ,ig/ml, then if more rapid absorption of metronidazole cani be promoted, higher serum concentrations may be obtained without increasing the dose administered.
The time-concentration curve (Fig. 3 ) indicates that there is plenty of time for radiation treatment to be given before the serum concentrationi falls appreciably. A further point to note is the long time required for complete elimination of the drug from the serum. Faster elimination may be helpful in reducing the duration of nauseous symptoms. As the drug is excreted in the urine largely unchanged, then adequate renal function and fluid intake are desirable.
The lack of toxicity, apart from nausea, associated with even the highest drug (lose employed is encouraging and agrees with the murine tumour experiments where no increased morbidity was associated with the increased cure rate (Begg et at., 1]974). One patient received a total of 55 g of metronidazole in less than 3 wNveeks (Table) and showed neither abnormal liver functioii test results nor blood couniits up to 3 weeks later. Doses of metronicdazole giving serum levels of 200 /ig/ml were on the borderline of acceptability to patients due to the nausea produced. Tolerance to doses of metronidazole of this order would be dependent on controlling nausea and would, in our experience, not be repeatable more than twice or perhaps 3 times a week.
It is concluded that peak serum concentrations of 200 ,ug/ml in patients could be reliably obtained with single doses of metronidazole of 180 mg/kg body weight. This is a smaller dose than that predicted from the studies in mice (Fig. 1) . Whether the enhancement ratio of 1 2 obtained for the single dose radiation treatment of the KHT sarcoma (Rauth and Kaufman, 1974) (Fletcher, 1973) . From the data of Schukovsky (1970) and Bush (1974) increases of 10-70% and 50-70O respectively would be predicted, and a formal clinical trial would be required to detect such increases.
